Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

Similar articles for PubMed (Select 23372640)

1.

Multi-centre observational study of transplacental transmission of influenza antibodies following vaccination with AS03(A)-adjuvanted H1N1 2009 vaccine.

Puleston R, Bugg G, Hoschler K, Konje J, Thornton J, Stephenson I, Myles P, Enstone J, Augustine G, Davis Y, Zambon M, Nicholson K, Nguyen-Van-Tam J.

PLoS One. 2013;8(1):e47448. doi: 10.1371/journal.pone.0047448. Epub 2013 Jan 23.

2.

Observational study to investigate vertically acquired passive immunity in babies of mothers vaccinated against H1N1v during pregnancy.

Puleston RL, Bugg G, Hoschler K, Konje J, Thornton J, Stephenson I, Myles P, Enstone J, Augustine G, Davis Y, Zambon M, Nicholson KG, Nguyen-Van-Tam JS.

Health Technol Assess. 2010 Dec;14(55):1-82. doi: 10.3310/hta14550-01.

3.

Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial.

Yang WH, Dionne M, Kyle M, Aggarwal N, Li P, Madariaga M, Godeaux O, Vaughn DW.

Vaccine. 2013 Sep 13;31(40):4389-97. doi: 10.1016/j.vaccine.2013.07.007. Epub 2013 Jul 12.

4.

Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity.

Langley JM, Reich D, Aggarwal N, Connor D, Lebel MH, Gupta A, Garfield H, Li P, Madan A, Vaughn DW.

Pediatr Infect Dis J. 2012 Aug;31(8):848-58. doi: 10.1097/INF.0b013e31825e6cd6.

PMID:
22801094
5.

Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants.

Ahmed SS, Schur PH, MacDonald NE, Steinman L.

J Autoimmun. 2014 May;50:1-11. doi: 10.1016/j.jaut.2014.01.033. Epub 2014 Feb 19. Review.

6.

Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age.

Waddington C, Andrews N, Hoschler K, Walker W, Oeser C, Reiner A, John T, Wilkins S, Casey M, Eccleston P, Allen R, Okike I, Ladhani S, Sheasby E, Waight P, Collinson A, Heath P, Finn A, Faust S, Snape M, Miller E, Pollard A.

Health Technol Assess. 2010 Oct;14(46):1-130. doi: 10.3310/hta14460-01.

7.

Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized study in adults aged 18-60 years and older.

Van Damme P, Kafeja F, Bambure V, Hanon E, Moris P, Roman F, Gillard P.

Hum Vaccin Immunother. 2013 Jul;9(7):1512-22. doi: 10.4161/hv.24504. Epub 2013 Apr 9.

PMID:
23571166
8.

Strong serological responses and HIV RNA increase following AS03-adjuvanted pandemic immunization in HIV-infected patients.

Calmy A, Bel M, Nguyen A, Combescure C, Delhumeau C, Meier S, Yerly S, Kaiser L, Hirschel B, Siegrist CA; H1N1 Study Group.

HIV Med. 2012 Apr;13(4):207-18. doi: 10.1111/j.1468-1293.2011.00961.x. Epub 2011 Nov 7.

PMID:
22093373
9.

The immunogenicity of a novel A (H1N1) vaccine in HIV-infected children.

Okike IO, Yung C, Ladhani S, Oeser C, Bennett A, Doerholt K, Storey S, Donaghy S, Butter N, Hoschler K, Sheasby L, Heath PT, Miller E.

Vaccine. 2011 Sep 2;29(38):6636-40. doi: 10.1016/j.vaccine.2011.06.103. Epub 2011 Jul 13.

PMID:
21742005
10.

Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months.

Carmona A, Omeñaca F, Tejedor JC, Merino JM, Vaman T, Dieussaert I, Gillard P, Arístegui J.

Vaccine. 2010 Aug 16;28(36):5837-44. doi: 10.1016/j.vaccine.2010.06.065. Epub 2010 Jun 29.

PMID:
20600478
11.

Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents.

Garcia-Sicilia J, Gillard P, Carmona A, Tejedor JC, Aristegui J, Merino JM, Behre U, Caplanusi A, Vaman T, Dieussaert I.

Vaccine. 2011 Jun 10;29(26):4353-61. doi: 10.1016/j.vaccine.2011.04.011. Epub 2011 Apr 17.

PMID:
21504774
12.

An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers.

Madhun AS, Akselsen PE, Sjursen H, Pedersen G, Svindland S, Nøstbakken JK, Nilsen M, Mohn K, Jul-Larsen A, Smith I, Major D, Wood J, Cox RJ.

Vaccine. 2010 Dec 16;29(2):266-73. doi: 10.1016/j.vaccine.2010.10.038. Epub 2010 Oct 27.

PMID:
21034828
13.

Influenza vaccination given at least 2 weeks before delivery to pregnant women facilitates transmission of seroprotective influenza-specific antibodies to the newborn.

Blanchard-Rohner G, Meier S, Bel M, Combescure C, Othenin-Girard V, Swali RA, Martinez de Tejada B, Siegrist CA.

Pediatr Infect Dis J. 2013 Dec;32(12):1374-80. doi: 10.1097/01.inf.0000437066.40840.c4.

PMID:
24569309
14.

AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial.

McElhaney JE, Beran J, Devaster JM, Esen M, Launay O, Leroux-Roels G, Ruiz-Palacios GM, van Essen GA, Caplanusi A, Claeys C, Durand C, Duval X, El Idrissi M, Falsey AR, Feldman G, Frey SE, Galtier F, Hwang SJ, Innis BL, Kovac M, Kremsner P, McNeil S, Nowakowski A, Richardus JH, Trofa A, Oostvogels L; Influence65 study group.

Lancet Infect Dis. 2013 Jun;13(6):485-96. doi: 10.1016/S1473-3099(13)70046-X. Epub 2013 Mar 19.

PMID:
23518156
15.

Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study.

Waddington CS, Walker WT, Oeser C, Reiner A, John T, Wilkins S, Casey M, Eccleston PE, Allen RJ, Okike I, Ladhani S, Sheasby E, Hoschler K, Andrews N, Waight P, Collinson AC, Heath PT, Finn A, Faust SN, Snape MD, Miller E, Pollard AJ.

BMJ. 2010 May 27;340:c2649. doi: 10.1136/bmj.c2649.

16.

Immune response after one or two doses of pandemic influenza A (H1N1) monovalent, AS03-adjuvanted vaccine in HIV infected adults.

Nielsen AB, Nielsen HS, Nielsen L, Thybo S, Kronborg G.

Vaccine. 2012 Nov 19;30(49):7067-71. doi: 10.1016/j.vaccine.2012.09.052. Epub 2012 Oct 2.

PMID:
23036498
17.

Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines.

Andrews NJ, Walker WT, Finn A, Heath PT, Collinson AC, Pollard AJ, Snape MD, Faust SN, Waight PA, Hoschler K, Sheasby L, Waddington C, Kerridge S, Chalk J, Reiner A, John T, Fletcher M, Allen R, Fineman N, Wilkins S, Casey M, Michaelis L, Oeser C, Okike I, Ladhani S, Miller E.

Vaccine. 2011 Oct 19;29(45):7913-9. doi: 10.1016/j.vaccine.2011.08.076. Epub 2011 Aug 27.

PMID:
21875635
18.

Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients.

Manuel O, Pascual M, Hoschler K, Giulieri S, Alves D, Ellefsen K, Bart PA, Venetz JP, Calandra T, Cavassini M.

Clin Infect Dis. 2011 Jan 15;52(2):248-56. doi: 10.1093/cid/ciq104.

19.

Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England.

Andrews N, Waight P, Yung CF, Miller E.

J Infect Dis. 2011 Jan 1;203(1):32-9. doi: 10.1093/infdis/jiq014.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk